TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03184805
Drug: Stopping aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject assigned to comparison arm will stop antiplatelet therapy before scheduled surgery or procedure. If subject is taking aspirin, clopidogrel, ticagrelor, or prasugrel, it should be discontinued for 7 days, 5 days, 3-5 days, and 7 days before surgery. Antiplatelet therapy may be restarted as previous regimen at fourth postoperative day or sooner unless significant bleeding risk or bleeding event occurs.
Study: NCT00366106
Drug: doxorubicin HCl liposome
Normalized name: DOXORUBICIN HCL LIPOSOME 2MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive intravenous doxorubicin HCl liposome injection given at 30 mg/m\^2 on Day 4 every 28 days (cycle).
Study: NCT04586270
Drug: TAS0612
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets
Study: NCT00139152
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline, Sub-Cuteanous (SQ)
Study: NCT02490436
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized cross-over between cetuximab and placebo
Study: NCT03720067
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20mg / day
Study: NCT03203525
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given via pump
Study: NCT03203525
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given via pump
Study: NCT03203525
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT06239155
Drug: AST-3424
Approvals — FDA: no, EMA: no, PMDA: no
Description: liquid formulation for Intravenous infusion
Study: NCT04094038
Drug: Glucose IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose 5%
Study: NCT00993694
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03070262
Drug: placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet, 3 tablets, tid, po
Study: NCT02891174
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: At the time of delivery, eligibility will be reviewed. If the participant remains eligible, she will be randomized by the study pharmacy to begin post-partum analgesic therapy with ibuprofen followed by acetaminophen.
Study: NCT02891174
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the time of delivery, eligibility will be reviewed. If the participant remains eligible, she will be randomized by the study pharmacy to begin post-partum analgesic therapy with acetaminophen followed by ibuprofen.
Study: NCT00445081
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00445081
Drug: Ciclosporine A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04124939
Drug: OnabotulinumtoxinA 100 Units
Normalized name: onabotulinumtoxinA 100 units injectable powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: BOTOX for injection is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for:~• Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication.
Study: NCT00266799
Drug: Pegylated liposomal doxorubicin (SCH 200746)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegylated liposomal doxorubicin (50 mg/m\^2 q 28 days) was administered intravenously until disease progression or unacceptable toxicity
Study: NCT00266799
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine (1250 mg/m\^2 BID x 14 days q 21 days) in tablets of 150 mg and 500 mg was administered orally, until disease progression or unacceptable toxicity
Study: NCT02250326
Drug: Duravalumab
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00248625
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible children were adaptively allocated within strata defined by age (less than 2 years of age or at least 2 years old) and hepatic encephalopathy (grade 0-1 or 2-4) to receive N-acetylcysteine (150 mg/kg/d) in 5% dextrose (D5W) and water or placebo consisting of an equal volume of D5W alone. Volumes were adjusted for small children. Study medications were infused over 24 hours for up to 7 consecutive days in a dedicated line without other medications. Treatment was stopped earlier than 7 days in the case of hospital discharge, liver transplantation, or death within 7 days of randomization.
Study: NCT00023959
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04851769
Drug: PCSK9 inhibitor plus statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the alirocumab arm will receive alirocumab 75 mg Q2W added to statin therapy (atorvastatin 20 mg/day or rosuvastatin 10mg/day).
Study: NCT04851769
Drug: standard statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will continue to receive atorvastatin 20 mg/day or rosuvastatin 10 mg/day.
Study: NCT01327625
Drug: azithromycin + N-acetylcystein + inhaled corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Azithromycin 500mg qd x 1 week --\> 250mg qod x 6 months~* N-acetylcystein 200mg tid x 6 months~* Fluticasone 250mcg puff x2/day x 6 months
Study: NCT02603146
Drug: HCQ Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: As described. Dosing will be based upon Screening IBW.
Study: NCT04375150
Drug: Tyrosine kinase inhibitor (TKI)
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TKIs
Study: NCT04375150
Drug: Immuno-oncology (IO)
Normalized name: Io-Shield
Approvals — FDA: no, EMA: no, PMDA: no
Description: IOs
Study: NCT02039115
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 weeks of placebo therapy will be given in the same manner as the prednisone arm after the first and second stage complete Barretts excision.
Study: NCT04633447
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered subcutaneously.
Study: NCT04145310
Drug: BOL-DP-o-04 + SCO
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual drops
Study: NCT04145310
Drug: Placebo + SCO
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual drops
Study: NCT01515813
Drug: Pravastatin sodium
Normalized name: Pravastatin Sodium
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 40 mg tablet of Pravastatin sodium taken orally once daily.
Study: NCT01515813
Drug: Pravastatin sodium
Normalized name: Pravastatin Sodium
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two 40mg tablets (80 mg total) of Pravastatin sodium taken orally once daily.
Study: NCT01234337
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine was administered orally at a dose of 1,000 mg/m\^2 twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Placebo matching to sorafenib was administered orally, 3 tablets (1 tablet in the morning, 2 tablets in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m\^2 twice daily and placebo dose to a total daily dose of 4 tablets (2 tablets twice daily) for that subject.
Study: NCT01234337
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m\^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle.days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m\^2 twice daily,
Study: NCT03231878
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00580827
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo.
Study: NCT00580827
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: disulfiram at 62.5 mg/day for 12 weeks.
Study: NCT00580827
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disulfiram at 125 mg/day for 12 weeks.
Study: NCT00580827
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: disulfiram at 250 mg/day for 12 weeks.
Study: NCT01978548
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered as 2 oral tablets once daily.
Study: NCT00572169
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given into the vein (IV) by a continuous infusion through a central catheter
Study: NCT03554473
Drug: M7824
Normalized name: M7824
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A \&amp; B: 2400mg IV over up to 120 minutes every 3 weeks on a 3-week cycle. Arm C: 1200 mg IV over 1 hour every 2 weeks on a 4-week cycle.
Study: NCT00006037
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01365195
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading and Infusion: Saline at infusion rate calculated and adjusted for weight to match ketamine bolus-infusion rate
Study: NCT01825759
Drug: danshen dripping pill
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01317368
Drug: Naropine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 0,75% Naropin is deposited on each side (40 mL in total) in the TAP.~At the same time 40 mL of saline 0,9% will be deposited subcutaneously as wound infiltration.~Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once.
Study: NCT01317368
Drug: Naropine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL Saline 0,9% is deposited on each side (40 mL in total) in the TAP.~At the same time 40 mL Ropivacaine 0,75% will be deposited subcutaneously as wound infiltration.~Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once.
Study: NCT03767933
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10mg/kg, maximum 600mg; Oral liquid
Study: NCT03767933
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15mg/kg, maximum 1000mg; Oral liquid
Study: NCT03767933
Drug: Acetaminophen placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral liquid
Study: NCT04750824
Drug: other systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: other systemic therapy
Study: NCT03859024
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: acetaminophen tablet
Study: NCT03859024
Drug: Ibuprofen 800 mg
Normalized name: ibuprofen 800 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ibuprofen tablet
Study: NCT01322711
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet
Study: NCT00907426
Drug: Vehicle solution
Normalized name: compounding vehicle solution sugar free no. 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, one drop of vehicle solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin).
Study: NCT02280265
Drug: Recombinant Human Coagulation Factor VIII for injection
Normalized name: coagulation factor VIII
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight 2 times one week) with ADVATE for 1 year.
Study: NCT02584660
Drug: Standard-of-care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care as per local protocol and defined by the medical team caring for the participant.
Study: NCT00969462
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: measurements of serum Doxorubicin levels
Study: NCT00171691
Drug: Diclofenac Topical Sodium Gel 1%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02297620
Drug: Suglat®
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01089075
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 20 mg po for 7 days (2 tablets)
Study: NCT04076293
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study will be conducted in approximately 5 sequential dosing cohorts, enrolling 8 subjects per cohort. Subjects will be randomized to HM15912 or placebo in a ratio of 6:2 (6 active, 2 placebo).
Study: NCT04244253
Drug: OPC-64005 20 mg , Once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active, High Dose
Study: NCT04244253
Drug: OPC-64005 10 mg , Once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active, Low Dose
Study: NCT04244253
Drug: Placebo, Once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00434876
Drug: Placebo.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive or inert pill which will be used as a comparator.
Study: NCT00780676
Drug: AZD6244
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg by mouth twice daily.
Study: NCT00212355
Drug: NPC-02
Normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: zinc acetate
Study: NCT00320619
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).
Study: NCT02753283
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semi-annual saline injection
Study: NCT01288742
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One 10-mg tablet for 1 day (Trt C).
Study: NCT01288742
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One 10-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt D.
Study: NCT01288742
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 150-mg capsule once daily for 7 days (Trts B and D).
Study: NCT01711359
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT01711359
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally every day
Study: NCT03124524
Drug: ethinylestradiol and drospirenone
Normalized name: drospirenone and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral,0.03 mg ethinylestradiol and 3 mg drospirenone (21 tablets)
Study: NCT02517502
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched, blinded placebo
Study: NCT04231773
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 parts per million dosage
Study: NCT04231773
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled placebo. Device connected to same delivery system, but does not deliver nitric oxide.
Study: NCT03683069
Drug: Eplerenone vs Amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: We posit that decreases in striatin activity/levels increases aldosterone secretion resulting in hypertension and salt sensitive blood pressure. Thus, our mechanistic clinical study will assess whether hypertensive striatin risk allele carriers will show significantly greater reductions in blood pressure with a specific aldosterone mediated treatment approach (mineralocorticoid receptor blockade) than with a non-specific approach (amlodipine). To test this hypothesis, we will perform a randomized, double-blind, active controlled study in hypertensive carriers of the striatin risk allele using a novel two-limb, proof-of-principle study. Our primary outcome will be a liberal salt diet systolic blood pressure with a secondary outcome of salt sensitive blood pressure. Therefore, this mechanistic trial will provide support for using a genetic marker that identifies individuals who are uniquely responsive to mineralocorticoid receptor blockade--personalized, precision medicine.
Study: NCT03070054
Drug: 20ml 0.25% bupivacaine-epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-capsular local infiltration analgesic (LIA) administration of 20ml 0.25% bupivacaine-epinephrine
Study: NCT03088345
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be started on a blinded continuous infusion of study drug/placebo in the OR, immediately following the completion of the MUF at 0.3 mU/kg/min. All caregivers will be blinded to the arm assignment. The infusion will run for 20 hours, at which time it will be weaned off at 0.1 mU/hr, over 3 hours.During the active study period, the care team will treat subjects per SOC, using any preferred medication to correct low cardiac output; there is no restriction on using open-label vasopressin during the active study treatment period.
Study: NCT00671658
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/m2 by vein
Study: NCT01888367
Drug: DFA-02 Antibiotic Gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01888367
Drug: DFA-02 Placebo Gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00671658
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2 by vein
Study: NCT00671658
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 12 mg intrathecally (6 mg if via Ommaya reservoir) for Courses 1,3,5,7~200 mg/m2 by vein followed by 800 mg/m2 for Courses 2,4,6,8
Study: NCT00671658
Drug: Solumedrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg by vein for Courses 2,4,6,8
Study: NCT01962935
Drug: AZD4721
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A - multiple ascending dose, daily; Part B - one dose decided after part A, daily
Study: NCT01962935
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A - multiple ascending dose daily
Study: NCT01962935
Drug: AZD5069
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part B - one dose decided after part A, twice a day
Study: NCT03195231
Drug: Wuling Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients of Wuling Group are instructed to take Wuling Powder 3 times a day and 3 pills each time for 12 weeks.
Study: NCT03195231
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients of Placebo Group are instructed to take placebo drug 3 times a day and 3 pills each time for 12 weeks.
Study: NCT02155725
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: As soon as possible and within 30 min following the start of prostaglandin infusion
Study: NCT03618160
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive SC injection of matching placebo on Day 1 in all cohorts of Part 1 and on Days 1, 8, 15, and 22 in Part 2 under fasted conditions.
Study: NCT03744975
Drug: LCZ 696
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Oral LCZ 696 (Entresto 97/103 mg)
Study: NCT03744975
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 1oral Placebo capsule
Study: NCT03444831
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone placebo QID after meal plus 20mg omeprazole before breakfast.
Study: NCT00660829
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01593826
Drug: Charcoal and Symbicort Turbuhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 inhalations as a single dose
Study: NCT01593826
Drug: Symbicort Turbuhaler forte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 inhalations as a single dose
Study: NCT02712346
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One inactive pill daily for twelve weeks
Study: NCT04375605
Drug: 5-Fluorouracil during radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: day 1 - 33: 225 mg/m²/day IV continuously
Study: NCT02250222
Drug: Placebo (Captisol ®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: betadex \[β-cyclodextrin\] sulfobutylether sodium, NF
Study: NCT03023449
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled Nitric Oxide gas
Study: NCT03658213
Drug: ZOLADEX 10.8 mg
Normalized name: Zoladex 10.8 MG Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.8 mg depot for injection (equivalent to 10.8 mg goserelin)
Study: NCT03658213
Drug: ZOLADEX 3.6mg
Normalized name: Zoladex 3.6mg Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 mg depot for injection (equivalent to 3.6 mg goserelin)
Study: NCT00986817
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: albumin perfusion at the dose 8 g/l of removed ascites and placebo, administrated before and at the end of the paracentesis.
Study: NCT03385395
Drug: OctaAlpha1
Approvals — FDA: no, EMA: no, PMDA: no
Description: For OctaAlpha1 the standard weekly dose of 60mg/kg will be given for 24 consecutive infusions
Study: NCT06749977
Drug: Remineralization with SAP11-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: The WSL were treated with SAP11-4 according to the manufacturer's instruction
Study: NCT01809158
Drug: minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01809158
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03525379
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized to receive one treatment: either resveratrol for 8 weeks OR placebo for 8 weeks. There will be a 2-week run-in period prior to the treatment period.
Study: NCT01004861
Drug: PLX3397
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules administered once or twice daily, continuous dosing
Study: NCT04361695
Drug: Ketoprophenum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprophenum